A new treatment for chronic pain, Arrhythmia and degeneration and behaviour disease (such as Schizophrenia, mania-depression, Alzheimers and Parkinsons diseases). Toxin-like Proteins, first found in the Bee brain function as an endogenous modulator...

A new treatment for chronic pain, Arrhythmia and degeneration and behaviour disease (such as Schizophrenia, mania-depression, Alzheimers and Parkinsons diseases). Toxin-like Proteins, first found in the Bee brain function as an endogenous modulator of voltage-gated Ca2+ channels. Platform technology with medical and non-medical applications including chronic pain, degeneration disease and behaviour diseases, Arrhythmia management, and bioinsecticide US patent

An effective treatment of chronic pain, Arrhythmia and degenerative diseases

Category	Chronic Pain, Arrhythmia and degenerative diseases
Development Stage	Peptide proof of concept
Patent Status	Patent pending
Market Size	The chronic pain (initial application) pharmaceutical and device market is expected to reach $47.5 billion in 2011 in the USA alone

Highlights

• A new treatment for chronic pain, Arrhythmia and degenerative and behaviour disease (such as Schizophrenia, mania-depression, Alzheimers and Parkinsons diseases)  
• Toxin-like Proteins, first found in the Bee brain function as an endogenous modulator of voltage-gated Ca2+ channels.
• Platform technology with medical and non-medical applications including chronic pain, degeneration disease and behaviour diseases, Arrhythmia management, and bioinsecticide

Our Innovation

• OCLP1 is predicted to be Calcium channel blocker
• Very small: a total of 28 amino acids

Key Features

• Minimal side-effects - function is extracellular ; thus, minimal toxicity
• Easily reproducible and non addictive
• Similar product found as effective non addictive morphine in AIDS patients.

Development Milestones

• Integrated three-module system (isolation, engineering and functional production) - 1 yr.
• Proof of concept in large animals - 1 yr.
• Clinical trials - 3 yrs.

The Opportunity

• USA Prevalence - Chronic Pain (50 million), Arrhythmia management (5 million), Degeneration and behaviour diseases (25 million)
• Economic Impact - Chronic Pain ($100 billion annualy), Arrhythmia management (1.2 million hospitalizations), Degeneration and behaviour diseases (Over $200 billion annualy)

project-id 27-2006-978

Patent pending